New roles for the femtosecond discussed. Subretinal implant disappoints. Genentech defends its actions relating to Avastin decision. Glaucoma pipeline looks very healthy, and much more.
Finnish researchers report on registry data and changing workload resulting from anti-VEGF therapies
The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
European Medicines Agency will assess semaglutide for link to NAION
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
A history of the femtosecond laser in the United States and Europe
The timeline demonstrates international innovation and collaboration
Balancing the promises and challenges of artificial intelligence
Sophisticated programmes require an evolving mindset